-transparent.png){kind=logo}
Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results. 2007
Gilles Raguin, and
Gwendoline Poizat, and
Laurence Morand-Joubert, and
Anne-Marie Taburet, and
Clotilde Le Tiec, and
François Clavel, and
Geneviève Chêne, and
Pierre-Marie Girard, and
Département de Medecine, Hôpital Croix-St-Simon, France.
We report the results of the extended follow-up at one year of a randomized trial evaluating the virological efficacy of a salvage therapy combining lopinavir and amprenavir with either 200 or 400 mg/day ritonavir, along with optimized nucleoside reverse transcriptase inhibitors, in patients carrying multidrug-resistant isolates. The combination of amprenavir, lopinavir and ritonavir (400 mg/day) is durably potent, yielding a sustained virological response (HIV RNA < 50 copies) in 39% of cases.
Related Publications
Gilles Raguin, and
Gwendoline Poizat, and
Laurence Morand-Joubert, and
Anne-Marie Taburet, and
Clotilde Le Tiec, and
François Clavel, and
Geneviève Chêne, and
Pierre-Marie Girard, and
August 2004,
Antiviral therapy,
Gilles Raguin, and
Gwendoline Poizat, and
Laurence Morand-Joubert, and
Anne-Marie Taburet, and
Clotilde Le Tiec, and
François Clavel, and
Geneviève Chêne, and
Pierre-Marie Girard, and
January 2004,
AIDS (London, England),
Gilles Raguin, and
Gwendoline Poizat, and
Laurence Morand-Joubert, and
Anne-Marie Taburet, and
Clotilde Le Tiec, and
François Clavel, and
Geneviève Chêne, and
Pierre-Marie Girard, and
August 2013,
Antimicrobial agents and chemotherapy,
Gilles Raguin, and
Gwendoline Poizat, and
Laurence Morand-Joubert, and
Anne-Marie Taburet, and
Clotilde Le Tiec, and
François Clavel, and
Geneviève Chêne, and
Pierre-Marie Girard, and
March 2002,
AIDS (London, England),
Gilles Raguin, and
Gwendoline Poizat, and
Laurence Morand-Joubert, and
Anne-Marie Taburet, and
Clotilde Le Tiec, and
François Clavel, and
Geneviève Chêne, and
Pierre-Marie Girard, and
November 2004,
The Journal of antimicrobial chemotherapy,
Gilles Raguin, and
Gwendoline Poizat, and
Laurence Morand-Joubert, and
Anne-Marie Taburet, and
Clotilde Le Tiec, and
François Clavel, and
Geneviève Chêne, and
Pierre-Marie Girard, and
October 2003,
HIV medicine,
Gilles Raguin, and
Gwendoline Poizat, and
Laurence Morand-Joubert, and
Anne-Marie Taburet, and
Clotilde Le Tiec, and
François Clavel, and
Geneviève Chêne, and
Pierre-Marie Girard, and
February 2002,
Antimicrobial agents and chemotherapy,
Gilles Raguin, and
Gwendoline Poizat, and
Laurence Morand-Joubert, and
Anne-Marie Taburet, and
Clotilde Le Tiec, and
François Clavel, and
Geneviève Chêne, and
Pierre-Marie Girard, and
December 2005,
The Journal of antimicrobial chemotherapy,
Gilles Raguin, and
Gwendoline Poizat, and
Laurence Morand-Joubert, and
Anne-Marie Taburet, and
Clotilde Le Tiec, and
François Clavel, and
Geneviève Chêne, and
Pierre-Marie Girard, and
October 2011,
The Journal of infectious diseases,
Gilles Raguin, and
Gwendoline Poizat, and
Laurence Morand-Joubert, and
Anne-Marie Taburet, and
Clotilde Le Tiec, and
François Clavel, and
Geneviève Chêne, and
Pierre-Marie Girard, and
October 2004,
The Pediatric infectious disease journal,
